Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

Hikma Pharmaceuticals KSA, announced the expansion of its strategic partnership with the Saudi Gastroenterology Association ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... and emphasized that other narcolepsy treatments are available. Hikma’s generic version of Xyrem only reached the market last ...

Hikma Pharmaceuticals (HIK – Research Report) received a Buy rating and a p2,400.00 price target from Berenberg Bank analyst Victoria Lambert yesterday. The company’s shares closed yesterday ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...